DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development
International Review of Cell and Molecular Biology · 2024
DOI: 10.1016/bs.ircmb.2024.05.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Review of Cell and Molecular Biology, 2024. Verfasst von Rajasekaran Subbarayan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Advanced Biotherapeutics and Regenerative Medicine, FAHS, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Edu…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunotherapy, Cancer Vaccines, DNA Damage. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 230 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) poses a significant clinical challenge due to its aggressive nature and limited therapeutic options. The interplay between DNA damage response (DDR) mechanisms and the emergence of neoantigens represents a promising avenue for developing targeted immunotherapeutic strategies and vaccines for TNBC. The DDR is a complex network of cellular mechanisms designed to maintain genomic integrity. In TNBC, where genetic instability is a hallmark, dysregulation of DDR components plays a pivotal role in tumorigenesis and progression. This review explores the intricate relationship between DDR and neoantigens, shedding light on the potential vulnerabilities of TNBC cells. Neoantigens, arising from somatic mutations in cancer cells, represent unique antigens that can be recognized by the immune system. TNBC's propensity for genomic instability leads to an increased mutational burden, consequently yielding a rich repertoire of neoantigens. The convergence of DDR and neoantigens in TNBC offers a distinctive opportunity for immunotherapeutic targeting. Immunotherapy has revolutionized cancer treatment by harnessing the immune system to selectively target cancer cells. The unique immunogenicity conferred by DDR-related neoantigens in TNBC positions them as ideal targets for immunotherapeutic interventions. This review also explores various immunotherapeutic modalities, including immune checkpoint inhibitors (ICIs), adoptive cell therapies, and cancer vaccines, that leverage the DDR and neoantigen interplay to enhance anti-tumor immune responses. Moreover, the potential for developing vaccines targeting DDR-related neoantigens opens new frontiers in preventive and therapeutic strategies for TNBC. The rational design of vaccines tailored to the individual mutational landscape of TNBC holds promise for precision medicine approaches. In conclusion, the convergence of DDR and neoantigens in TNBC presents a compelling rationale for the development of innovative immunotherapies and vaccines. Understanding and targeting these interconnected processes may pave the way for personalized and effective interventions, offering new hope for patients grappling with the challenges posed by TNBCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Advanced Biotherapeutics and Regenerative Medicine, FAHS, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, India.
- Department of Psychiatry, Washington university School of Medicine, St louis, MO, United States.
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, United States. Electronic address: salman.usmani@einsteinmed.edu.
- Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States. Electronic address: nityanand.srivastava@einsteinmed.edu.
Zitieren
APA
Subbarayan, R., Srinivasan, D., Balakrishnan, R., Kumar, A., Usmani, S. S., & Srivastava, N. (2024). DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development. International Review of Cell and Molecular Biology. https://doi.org/10.1016/bs.ircmb.2024.05.001
Vancouver
Subbarayan R, Srinivasan D, Balakrishnan R, Kumar A, Usmani SS, Srivastava N. DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development. International Review of Cell and Molecular Biology. 2024. doi:10.1016/bs.ircmb.2024.05.001
BibTeX
@article{Subbarayan2024,
author = {Subbarayan, Rajasekaran and Srinivasan, Dhasarathdev and Balakrishnan, Ranjith and Kumar, Ajeet and Usmani, Salman Sadullah and Srivastava, Nityanand},
title = {DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development},
journal = {International Review of Cell and Molecular Biology},
year = {2024},
doi = {10.1016/bs.ircmb.2024.05.001}
}
EUVIMED